We are live on ! Find out more

ClearPoint Neuro

CLPT

Market cap $408M

13.37 USD

-0.09

0.67%

At close Updated Sep 15, 1:11 PM EDT

1 day

-0.67%

5 days

-4.09%

1 month

-13.74%

3 months

-1.11%

6 months

21.21%

Year to date

-4.7%

1 year

27.7%

5 years

-25.64%

10 years

242.82%

About: ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.

Employees: 172

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 70%

Negative 10%

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

Zacks Investment Research

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.21 per share a year ago.

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro NASDAQ: CLPT reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery.

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro Reports Second Quarter 2026 Results

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Highlights Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharma customers supporting new trial initiations compared to the second quarter a year ago.

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

SOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 second quarter on Monday, August 3rd, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 second quarter on Monday, August 3rd at 4:30 p.m.

ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026

ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case

ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure's AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT's Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations.

ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case

Zacks Investment Research

ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?

ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ClearPoint Neuro (CLPT) Surges 26.0%: Is This an Indication of Further Gains?

See News Rankings

Price charts implemented using Lightweight Charts™